Venture capital investment in biopharmaceutical companies is booming in 2020. And while novel cancer and immuno-oncology programs continue to attract large sums, drug developers working on treatments for neurological diseases also are raising sizeable venture rounds. Among six companies with recently announced financings, Nura Bio Inc. launched with $73m in series A cash and Encoded Therapeutics Inc. closed a $135m series D round.
Pitchbook and the National Venture Capital Association (NVCA) reported in their Venture Monitor report earlier this month that biopharma companies...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?